Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX)
Health Care · Biotechnology · US
$2.20
+2.09% today · -24.9% 1Y
Black Diamond Therapeutics, Inc. (NasdaqGS: BDTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $123.81M and employs 21 people.
Over the last twelve months the share price has lost 24.9%, trading between 1.60 and 4.94.
Tweenvest scores Black Diamond Therapeutics, Inc. across four factors: quality 51/100. Its strongest factor is quality.
BDTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $123.81M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.74
- Dividend yield
- —
- Beta (5Y)
- 3.29
- 52-week high
- $4.94
- 52-week low
- $1.60
- Avg volume (3M)
- —
- Shares outstanding
- 57.45M
- Employees
- 21
- Next earnings
- —
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
- ISIN
- US09203E1055
- Founded
- 2014
- Listed since
- Jan 31, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.16 | -0.14% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.77 | +0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $550.00 | +0.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | 0.00% |
| argenx SEENXTBR: ARGX | $63.06B | €873.60 | +1.09% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.58 | +1.94% |
Figures last refreshed Aug 18, 2026.